Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma

Abstract Background BRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation frequency and their correlation with histological characteristics in Slovenian population have not been investigated yet. Patients and methods In our retrospective analysis we analysed mutational status of BRAF, NRAS and c-KIT in 230 pathological samples of patients who were intended to be treated with systemic therapy due to metastatic disease at the Institute of Oncology Ljubljana between 2013 and 2016. We collected also histological characteristics of primary tumours and clinical data of patients and correlated them with mutational status of tumour samples. Results The study population consisted of 230 patients with a mean age 59 years (range 25−85). 141 (61.3%) were males and 89 (38.7%) females. BRAF mutations were identified in 129 (56.1%), NRAS in 31 (13.5%) and c-KIT in 3 (1.3%) tissue samples. Among the 129 patients with BRAF mutations, 114 (88.4%) patients had V600E mutation and 15 (11.6%) had V600K mutation. Patients with BRAF mutations tended to be younger at diagnosis (52 vs. 59 years, p < 0.05), patients with NRAS mutations older (61 vs. 55 years, p < 0.05). Number of c-KIT mutations were too low for any statistical correlation, but there was one out of 3 melanoma located in mucus membranes. Conclusions The analysis detected high rate of BRAF mutations, low NRAS mutations and low c-KIT mutations compared to previously published studies in Europe and North America. One of the main reasons for this observation is specific characteristics of study population.

[1]  G. Ullenhag,et al.  Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. , 2017, European journal of cancer.

[2]  V. Zadnik,et al.  Cancer burden in slovenia with the time trends analysis , 2017, Radiology and oncology.

[3]  J. Mosser,et al.  Prognostic and predictive values of oncogenic BRAF, NRAS, c‐KIT and MITF in cutaneous and mucous melanoma , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  Soo-Nyung Kim,et al.  Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. , 2015, Journal of the American Academy of Dermatology.

[5]  A. Iafrate,et al.  Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies , 2015, Cancer Immunology Research.

[6]  K. Tsuta,et al.  BRAF V600 mutations and pathological features in Japanese melanoma patients , 2014, Melanoma research.

[7]  R. Scolyer,et al.  Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma , 2014, British Journal of Cancer.

[8]  O. Griffith,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[9]  Michael A. Davies,et al.  Pathways and therapeutic targets in melanoma , 2014, Oncotarget.

[10]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[11]  M. Mandalà,et al.  Targeting BRAF in melanoma: biological and clinical challenges. , 2013, Critical reviews in oncology/hematology.

[12]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[13]  C. Ng,et al.  NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.

[14]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[15]  G. Botti,et al.  BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[17]  C. Tzen,et al.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.

[18]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[19]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Scolyer,et al.  BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.

[21]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[22]  A. Hauschild,et al.  Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Shicai Wang,et al.  COSMIC: the Catalogue Of Somatic Mutations In Cancer , 2018, Nucleic Acids Res..

[24]  J. Lundeberg,et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.

[25]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[27]  A. Hauschild,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.